Core Scientific, Inc./tx (CORZR) SEC Filings

Core Scientific, Inc. (CORZ) reports updated electrical power status for its existing and planned data centers in Texas under ERCOT’s large-load review framework. At Denton, 297 Megawatts of existing power has been conditionally approved as “Base Load, Pathway (a)” and is classified as longstanding existing load not subject to the Batch Zero allocation process. An additional 74 Megawatts at Denton was previously incorporated in ERCOT’s 2025 Regional Transmission Plan study cases and is also outside the Batch Zero process.

At Pecos, 300 Megawatts of existing power and an additional 300 Megawatts of “Studied Load” have been conditionally approved in Batch Zero as “Base Load, Pathway (b).” All required documentation and financial collateral for Pecos have been submitted and posted, though final allocation and load ramp will follow completion of Batch Zero. At Hunt, 431 Megawatts of planned power has been conditionally approved in Batch Zero as “Base Load, Advancing Large Load, Pathway (e),” with interconnection studies completed, ERCOT stability approval received, financial collateral posted, long-lead equipment ordered, and construction commenced.

Core Scientific, Inc. (CORZ) officer Todd M. Duchene, Chief Legal and Administrative Officer, reported selling 10,000 shares of common stock on August 31, 2026 at a weighted average price of $16.23 per share under a Rule 10b5-1 trading plan. After this sale, he held 1,927,896 shares directly.

Core Scientific, Inc. (CORZ) entered into committed senior secured credit facilities totaling $600 million, comprised of a $100 million senior secured revolving credit facility and a $500 million letter of credit facility with a syndicate of banks led by JPMorgan Chase Bank, N.A. The facilities mature on the third anniversary of August 25, 2026, or, at the company’s election, the fourth anniversary, and are secured by a first‑priority lien on substantially all assets of Core Scientific and certain wholly owned domestic subsidiaries, which also guarantee the obligations.

Borrowings under the revolver bear interest at Adjusted Term SOFR + 1.750% (0.00% floor) or an alternate base rate + 0.75%. Letters of credit incur a 1.750% annual fee plus a 0.125% quarterly fronting fee, and a 0.250% annual commitment fee applies to unused portions of the facilities. As of closing, no amounts were outstanding, and the company disclosed a quarterly liquidity covenant of at least $150 million and a minimum market capitalization of $3,000 million as a condition to each borrowing under the revolver. A related press release states the facilities are expected to release approximately $300 million of restricted cash, improving capital efficiency as Core Scientific continues shifting its digital infrastructure business toward high‑density colocation services for AI‑related workloads.

Core Scientific, Inc. (CORZ) reported that its Chief Legal and Administrative Officer, Todd M. Duchene, sold 10,000 shares of common stock on August 24, 2026 in an open-market transaction at a weighted average price of $17.4493 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. After this transaction, Duchene directly holds 1,937,896 shares of Core Scientific common stock.

The filing notes that the 10,000 shares were sold in multiple trades at prices ranging from $17.17 to $17.77 per share.

Core Scientific, Inc. (CORZ) director Elizabeth Crain purchased Core Scientific common stock in the open market. She bought 6,000 shares of common stock on 2026-08-20 at a weighted average price of $18.3324 per share, in multiple trades between $18.27 and $18.345. Following this transaction, she directly holds 71,348 shares of Core Scientific common stock.

Core Scientific, Inc./tx (CORZ) director Eric Stanton Weiss reported an open-market purchase of 7,000 shares of Common Stock on August 18, 2026, at a weighted average price of $19.194 per share. After this transaction, he directly holds 259,262 CORZ shares. The price reflects multiple trades between $18.785 and $19.595 per share.

Core Scientific, Inc. (CORZ) insider Todd M. Duchene, the Chief Legal and Administrative Officer, reported transactions in Common Stock on August 17, 2026. He sold 10,000 shares in an open-market or private transaction at a weighted average price of $20.0974 per share, with individual sale prices ranging from $19.74 to $20.42. In a separate transaction the same day, 11,205 shares of common stock were disposed of to satisfy withholding tax obligations upon the vesting of restricted stock units. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025.

Pentwater Capital Management LP and Matthew Halbower report beneficial ownership of Core Scientific, Inc. common stock on a Schedule 13G/A. They collectively report 1,336,594 shares of Common Stock, including 800,000 shares issuable upon exercise of options, representing 0.4% of the class based on 317,885,292 shares outstanding as of May 1, 2026. All voting and dispositive authority over these shares is reported as shared, with no sole voting or dispositive power.

Jericho Capital Asset Management L.P. and Josh Resnick report beneficial ownership of Core Scientific, Inc. common stock. They collectively hold 22,882,942 shares of common stock, representing 7.2% of the class.

Both reporting persons have shared voting power over 22,882,942 shares and shared dispositive power over 22,882,942 shares, with no sole voting or dispositive power. Jericho Capital Asset Management L.P. acts as investment adviser to certain investment funds and accounts that have the right to receive or direct dividends and sale proceeds from these shares. Josh Resnick is identified as a reporting person and managing member associated with the adviser. The reporting persons have entered into a joint filing agreement covering this ownership report.